Loading…
BioCardia, Inc. is projected to rise to $1.00 by 2027, a +9% move from its current price of $0.9148. BCDA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.872 | $0.9155 | $0.9612 | +0.08% |
| Jul 14 | $0.8552 | $0.9162 | $0.9815 | +0.15% |
| Jul 15 | $0.8428 | $0.9169 | $0.9976 | +0.23% |
| Jul 16 | $0.8325 | $0.9176 | $1.01 | +0.31% |
| Jul 17 | $0.8236 | $0.9183 | $1.02 | +0.39% |
| Jul 18 | $0.8157 | $0.919 | $1.04 | +0.46% |
| Jul 19 | $0.8086 | $0.9198 | $1.05 | +0.54% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8086 | $0.9198 | $1.05 | +0.54% |
| Week 2 | $0.7707 | $0.9247 | $1.11 | +1.09% |
| Week 3 | $0.7438 | $0.9297 | $1.16 | +1.63% |
| Week 4 | $0.7224 | $0.9348 | $1.21 | +2.18% |
| Week 5 | $0.7046 | $0.9398 | $1.25 | +2.74% |
| Week 6 | $0.6892 | $0.9449 | $1.30 | +3.29% |
| Week 7 | $0.6756 | $0.95 | $1.34 | +3.85% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC.
BioCardia, Inc. is based in Sunnyvale, California.
BioCardia, Inc. (BCDA) is a Healthcare company with a current price of $0.8924. The market capitalization is $13.28M, and the stock is ranked 5060. The current price is quoted alongside a near-term technical picture that is mixed with ongoing softness in recent sessions.
The stock trades in a low-price, small-cap space with notable volatility implied by its historical range and indicator readings.
A major floor 40.6% below — a decisive break under it would weaken the trend.
The nearest floor, 12.5% below — buyers have tended to step in here.
The nearest ceiling, 35.5% above — a clean break opens room to run.
A major ceiling 55.6% above — clearing it would confirm fresh momentum.
Key BCDA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCDA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.992 | Sell | $0.9782 | Sell |
| MA 10 | $1.10 | Sell | $1.02 | Sell |
| MA 20 | $1.02 | Sell | $1.03 | Sell |
| MA 50 | $1.00 | Sell | $1.04 | Sell |
| MA 100 | $1.11 | Sell | $1.11 | Sell |
| MA 200 | $1.22 | Sell | $1.33 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.96 | Neutral |
| Stoch RSI (14) | 5.81 | Buy |
| CCI (20) | -62.08 | Neutral |
| Williams %R (14) | -94.29 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -9.00 | Sell |
| Bollinger %B (20,2) | 0.30 | Neutral |
| Stochastic %K (14) | 5.71 | Buy |
| TRIX (15) | 0.45 | Buy |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 24.42 | Buy |
| Momentum (10) | -0.18 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 0.87 | Buy |
| ADX (14) | 21.14 | Sell |
| ATR (14) | 0.05 | Info |
The 30-day range spans from $0.6421 to $1.24, illustrating a wide swing within the near-term window. The price sits around $0.8924, indicating a modest step above the lower end of the range. The RSI14 is 40, and the sentiment is bearish, with the price trading below the 50-day simple moving average of $1.01 and the 200-day simple moving average of $1.22.
Support is at $0.80 and resistance at $1.24, providing a defined but narrow near-term trading framework. The annualized volatility is 100%, underscoring the high variability typical of this small-cap growth-focused name.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.80 | $0.9148 | $1.42 | 0% | Neutral | |
| $0.7384 | $1.00 | $1.46 | +9% | Neutral | |
| $0.6766 | $0.9677 | $1.50 | +6% | Neutral | |
| $0.6292 | $0.9423 | $1.53 | +3% | Neutral | |
| $0.5107 | $0.7975 | $1.34 | -13% | Neutral | |
| $0.6863 | $1.11 | $1.94 | +22% | Bullish | |
| $0.8094 | $1.36 | $2.44 | +49% | Bullish | |
| $0.7121 | $1.24 | $2.28 | +36% | Bullish | |
| $0.7479 | $1.35 | $2.54 | +48% | Bullish | |
| $0.677 | $1.26 | $2.43 | +38% | Bullish | |
| $0.8291 | $1.81 | $3.82 | +98% | Bullish | |
| $1.66 | $3.68 | $8.47 | +303% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.80 | $0.9148 | $1.14 | +0.00% |
| August 2026 | $0.8233 | $0.9925 | $1.24 | +8.49% |
| September 2026 | $0.8038 | $0.9814 | $1.25 | -1.11% |
| October 2026 | $0.7793 | $0.9621 | $1.25 | -1.97% |
| November 2026 | $0.8174 | $1.02 | $1.34 | +5.89% |
| December 2026 | $0.8493 | $1.07 | $1.42 | +4.82% |
Click any year to see its month-by-month BCDA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BCDA is projected to trade between $0.80 and $1.42, averaging $0.9148 — a potential gain of 0% from today's $0.9148. A consolidation phase looks the most probable path here.
BioCardia, Inc.'s 2027 outlook centres on $1.00, within a $0.7384 to $1.46 range. That is up +9% on the projected 2026 average. That marks a +9% change versus current levels. Price action looks broadly range-bound.
By 2028, BCDA could reach as high as $1.50, with a base case around $0.9677 and support toward $0.6766 — roughly +6% from $0.9148. A consolidation phase looks the most probable path here.
Expect BCDA to range from $0.6292 to $1.53 through 2029. The $0.9423 average target implies a +3% move from current prices. That is -3% versus the projected 2028 average. Price action looks broadly range-bound.
The BCDA price prediction for 2030 points to an average of $0.7975 (low $0.5107, high $1.34) — a potential decline of -13% on today's $0.9148. A consolidation phase looks the most probable path here.
In 2031, BCDA is projected to trade between $0.6863 and $1.94, averaging $1.11 — a potential gain of +22% from today's $0.9148. That is up +40% on the projected 2030 average. Momentum favours further upside here.
BioCardia, Inc.'s 2032 outlook centres on $1.36, within a $0.8094 to $2.44 range. That is up +22% on the projected 2031 average. That marks a +49% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, BCDA could reach as high as $2.28, with a base case around $1.24 and support toward $0.7121 — roughly +36% from $0.9148. Momentum favours further upside here.
Expect BCDA to range from $0.7479 to $2.54 through 2034. The $1.35 average target implies a +48% move from current prices. That is up +9% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The BCDA price prediction for 2035 points to an average of $1.26 (low $0.677, high $2.43) — a potential gain of +38% on today's $0.9148. Momentum favours further upside here.
In 2040, BCDA is projected to trade between $0.8291 and $3.82, averaging $1.81 — a potential gain of +98% from today's $0.9148. That is up +44% on the projected 2035 average. Buyers look set to stay in control over this stretch.
BioCardia, Inc.'s 2050 outlook centres on $3.68, within a $1.66 to $8.47 range. That is up +103% on the projected 2040 average. That marks a +303% change versus current levels. Momentum favours further upside here.
Investing $1,000 in BCDA today (≈ 1,093.135111 BCDA) could be worth
$4,027.5
+$3,027.5 (+303%) by 2050 · US Dollar
Based on the average projected BCDA price of $3.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCDAwould be worth at today's price.
$1,000 invested in BCDA on Jul 10, 2025 (≈ 413.223127 BCDA) would be worth
$378.02
-$621.98 (-62.2%) today · 0.38× · US Dollar
Based on a BCDA entry price of $2.42 vs. today's $0.9148.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.2 | $762.33 | -23.8% |
| 1 month ago | $0.81 | $1,129.38 | +12.9% |
| 3 months ago | $1.18 | $775.25 | -22.5% |
| 6 months ago | $1.42 | $644.23 | -35.6% |
| 1 year ago | $2.42 | $378.02 | -62.2% |
| All time (5.0y) ago | $52.95 | $17.28 | -98.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCDA forecast.
Our base-case forecast reaches $1.80 around 2040.
Implied market cap at $1.80: $26.79M
The year-by-year forecast shows a transition from neutral to bullish sentiment over time, with notable upside in the later years. In 2026 the min is $0.80, the avg is $0.8924, and the max is $1.40, with an ROI of 0 and a NEUTRAL stance. In 2031 the avg rises to $1.10 with a max of $1.92 and an ROI of 22.8, supported by a BULLISH outlook.
2032 projects a strong move to an avg of $1.34 and a max of $2.42 with an ROI of 49.8, continuing the bullish trajectory through 2033 (avg $1.21, max $2.25, ROI 35.7) and 2034 (avg $1.33, max $2.52, ROI 48.8) and 2035 (avg $1.23, max $2.39, ROI 38). The forecast then accelerates, with 2040 showing an avg of $1.78 and a max of $3.80, ROI 99.9, under a BULLISH sentiment. By 2050, the avg is $3.63 with a max of $8.35 and aROI of 306.8, with a BULLISH stance continuing.
These figures imply substantial longer-term upside but also highlight meaningful risk around the 2030 period when the ROI turns negative at -13.5. While the late-year outsized returns are possible, they hinge on factors outside the numerical forecast and are not guaranteed.
Tap a question to reveal the answer.
The 2030 forecast shows min $0.4896, avg $0.7717, max $1.31 with ROI -13.5 and a NEUTRAL sentiment.
Near-term outlook through 2029 is NEUTRAL, with a notable shift to BULLISH from 2031 onward and ROIs such as 22.8 (2031) and 306.8 (2050) in the longer term, offering upside but accompanied by uncertainty and potential drawdowns (e.g., -13.5 in 2030).
Yes. The forecast max reaches $2.42 in 2032 and $2.52 in 2034, with higher aspirational levels later (2040 max $3.80 and 2050 max $8.35).
The current price is $0.8924.
The 2050 forecast lists min $1.63, avg $3.63, max $8.35 with ROI 306.8 and a BULLISH sentiment.
BioCardia, Inc. Community Discussion
0Share your BioCardia, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.